Biologics

Overcome Barriers in Biologics-Based Discovery

Genedata Biologics offers a comprehensive platform designed to enhance innovation in biopharmaceutical research and development. It provides ready-to-use functionalities that support the entire biopharma discovery workflow, including the development of antibodies, bispecifics, antibody-drug conjugates (ADCs), T-cell receptors (TCRs), chimeric antigen receptor T-cells (CAR-Ts), and adeno-associated viruses (AAVs).

This platform serves as a central repository for R&D groups, enabling real-time access to TCR-related information throughout the workflow. It supports various development processes such as Immatics’ ACTengine, ACTallo, and TCER bispecific TCR molecule development.

Genedata Biologics tracks biologics molecules from early discovery through development stages, providing organizations like UCB with centralized access to all pertinent data. It acts as a backbone for streamlining large-molecule R&D processes, ensuring efficiency and scalability.

Key features include:

• End-to-end support for diverse and data-intensive workflows.
• Centralized data access for streamlined communication and traceability.
• Enhanced efficiency in screening, engineering, production, and testing of complex multi-specific antibody candidates.

Organizations such as Pfizer have adopted this system to enhance their antibody discovery and protein engineering capabilities, while others have recognized it as a leading platform for antibody R&D workflows.

The platform's Request Management System standardizes intergroup communication, reducing ad hoc interactions and improving overall process efficiency.